Ocular Therapeutix, Inc.
US ˙ NasdaqGM ˙ US67576A1007

SecurityOCUL / Ocular Therapeutix, Inc.
InstitutionAxa S.a.
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Axa S.a. closes position in OCUL / Ocular Therapeutix, Inc.

On November 14, 2025 - Axa S.a. filed a 13F-HR form disclosing ownership of 0 shares of Ocular Therapeutix, Inc. (US:OCUL) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 516,500 shares of Ocular Therapeutix, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F OCULAR THERAPEUTIX COM 67576A100 0 -516,500 -100.00 0 -100.00
2025-08-14 2025-06-30 13F OCULAR THERAPEUTIX COM 67576A100 516,500 -43,019 -7.69 4,793 16.87 0.0138
2025-05-15 2025-03-31 13F OCULAR THERAPEUTIX COM 67576A100 559,519 -78,313 -12.28 4,101 -24.71 0.0135
2025-02-14 2024-12-31 13F OCULAR THERAPEUTIX COM 67576A100 637,832 -1,015 -0.16 5,447 -1.98 0.0165
2024-11-14 2024-09-30 13F OCULAR THERAPEUTIX COM 67576A100 638,847 182 0.03 5,558 27.22 0.0165
2025-02-25 2024-06-30 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 638,665 360 0.06 4,368 -24.79 0.0130
2024-08-14 2024-06-30 13F OCULAR THERAPEUTIX COM 67576A100 638,665 360 4,368 0.0130
2024-05-15 2024-03-31 13F OCULAR THERAPEUTIX COM 67576A100 638,305 179 0.03 5,809 104.08 0.0174
2024-07-16 2023-12-31 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 638,126 -1,108 -0.17 2,846 41.80 0.0092
2024-02-14 2023-12-31 13F OCULAR THERAPEUTIX COM 67576A100 638,126 -1,108 2,846 0.0056
2023-11-14 2023-09-30 13F OCULAR THERAPEUTIX COM 67576A100 639,234 164,334 34.60 2,007 -18.08 0.0071
2023-08-14 2023-06-30 13F OCULAR THERAPEUTIX COM 67576A100 474,900 474,900 2,450 0.0081
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.